Daniel Valerio1, Henriette Raventos2, James Schmeidler3, Michal S Beeri4, Lara Mora Villalobos5, Patricia Bolaños-Palmieri5, José R Carrión-Baralt6, Jaime Fornaguera7, Jeremy M Silverman8. 1. Hospital Nacional de Geriatría y Gerontología de Costa Rica, San José, Costa Rica; School of Medicine, Universidad de Costa Rica, San José, Costa Rica. 2. Centro de Investigación en Biología Molecular y Celular, Universidad de Costa Rica, San José, Costa Rico; Escuela de Biología, Universidad de Costa Rica, San José, Costa Rica. 3. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY; The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Aviv, Israel. 5. Centro de Investigación en Biología Molecular y Celular, Universidad de Costa Rica, San José, Costa Rico. 6. Gerontology Program, Department of Human Development, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, Rio Piedras, Puerto Rico. 7. Centro de Investigación en Neurociencias, Universidad de Costa Rica, San José, Costa Rica. 8. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Research and Development Service, James J. Peters Veterans Affairs Medical Center, Bronx, NY. Electronic address: jeremy.silverman@mssm.edu.
Abstract
OBJECTIVE: To study the association of dementia with apolipoprotein E-e4 (APOE-e4) and its interaction with age in a nonagenarian Costa Rican group (N-sample) and a general elderly contrast group (GE-sample). METHODS: In both case-control studies, participants were cognitively intact or diagnosed with dementia. The N-sample (N = 112) was at least age 90 years; the GE-sample (N = 98) was at least age 65 years. RESULTS: Dementia and APOE-e4 were not significantly associated in the N-sample, but were in the GE-sample. There was a significant interaction of age with APOE-e4 in the N-sample, but not in the GE-sample. Descriptively dividing the N-sample at the median (age 93 years) showed a group interaction: APOE-e4 was more associated with dementia in the younger N-sample than in the older N-sample, where six of seven APOE-e4 carriers were cognitively intact. CONCLUSIONS: The results support the reduction in association of APOE-e4 with dementia in extreme old age, consistent with a survivor effect model for successful cognitive aging. Published by Elsevier Inc.
OBJECTIVE: To study the association of dementia with apolipoprotein E-e4 (APOE-e4) and its interaction with age in a nonagenarian Costa Rican group (N-sample) and a general elderly contrast group (GE-sample). METHODS: In both case-control studies, participants were cognitively intact or diagnosed with dementia. The N-sample (N = 112) was at least age 90 years; the GE-sample (N = 98) was at least age 65 years. RESULTS:Dementia and APOE-e4 were not significantly associated in the N-sample, but were in the GE-sample. There was a significant interaction of age with APOE-e4 in the N-sample, but not in the GE-sample. Descriptively dividing the N-sample at the median (age 93 years) showed a group interaction: APOE-e4 was more associated with dementia in the younger N-sample than in the older N-sample, where six of seven APOE-e4 carriers were cognitively intact. CONCLUSIONS: The results support the reduction in association of APOE-e4 with dementia in extreme old age, consistent with a survivor effect model for successful cognitive aging. Published by Elsevier Inc.
Authors: José R Carrión-Baralt; Josefina Meléndez-Cabrero; Heide Rodríguez-Ubiñas; James Schmeidler; Michal Schnaider Beeri; Gary Angelo; Mary Sano; Jeremy M Silverman Journal: J Alzheimers Dis Date: 2009 Impact factor: 4.472
Authors: Jeremy M Silverman; James Schmeidler; Michal S Beeri; Clive Rosendorff; Mary Sano; Hillel T Grossman; José R Carrión-Baralt; Irina N Bespalova; Rebecca West; Vahram Haroutunian Journal: Neurology Date: 2012-08-15 Impact factor: 9.910
Authors: Tiffany A Greenwood; Michal S Beeri; James Schmeidler; Daniel Valerio; Henriette Raventós; Lara Mora-Villalobos; Karla Camacho; José R Carrión-Baralt; Gary Angelo; Laura Almasy; Mary Sano; Jeremy M Silverman Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: James Schmeidler; Cecilia N Mastrogiacomo; Michal S Beeri; Clive Rosendorff; Jeremy M Silverman Journal: Int Psychogeriatr Date: 2019-02-05 Impact factor: 3.878
Authors: Laura B Zahodne; Nicole Schupf; Adam M Brickman; Richard Mayeux; Melanie M Wall; Yaakov Stern; Jennifer J Manly Journal: J Alzheimers Dis Date: 2016-04-12 Impact factor: 4.472
Authors: Diddier Prada; Elena Colicino; Melinda C Power; David G Cox; Marc G Weisskopf; Lifang Hou; Avron Spiro Iii; Pantel Vokonas; Jia Zhong; Marco Sanchez-Guerra; Luis A Herrera; Joel Schwartz; Andrea A Baccarelli Journal: BMC Psychiatry Date: 2014-08-01 Impact factor: 3.630
Authors: A Lacour; A Espinosa; E Louwersheimer; S Heilmann; I Hernández; S Wolfsgruber; V Fernández; H Wagner; M Rosende-Roca; A Mauleón; S Moreno-Grau; L Vargas; Y A L Pijnenburg; T Koene; O Rodríguez-Gómez; G Ortega; S Ruiz; H Holstege; O Sotolongo-Grau; J Kornhuber; O Peters; L Frölich; M Hüll; E Rüther; J Wiltfang; M Scherer; S Riedel-Heller; M Alegret; M M Nöthen; P Scheltens; M Wagner; L Tárraga; F Jessen; M Boada; W Maier; W M van der Flier; T Becker; A Ramirez; A Ruiz Journal: Mol Psychiatry Date: 2016-03-15 Impact factor: 15.992
Authors: Jeremy M Silverman; James Schmeidler; Pearl G Lee; Neil B Alexander; Michal Schnaider Beeri; Elizabeth Guerrero-Berroa; Rebecca K West; Mary Sano; Martina Nabozny; Carolina Rodriguez Alvarez Journal: Alzheimers Dement (N Y) Date: 2019-12-11